SAGE — Sage Therapeutics Income Statement
0.000.00%
- $653.58m
- -$63.44m
- $86.46m
- 30
- 23
- 23
- 15
Annual income statement for Sage Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.87 | 1,114 | 6.31 | 7.69 | 86.5 |
Cost of Revenue | |||||
Gross Profit | 6.47 | 1,114 | 5.75 | 6.87 | 84.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 715 | 518 | 467 | 555 | 666 |
Operating Profit | -708 | 596 | -461 | -547 | -580 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -680 | 606 | -458 | -533 | -541 |
Net Income After Taxes | -680 | 606 | -458 | -533 | -541 |
Net Income Before Extraordinary Items | |||||
Net Income | -680 | 606 | -458 | -533 | -541 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -680 | 606 | -458 | -533 | -541 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -13.4 | 12 | -7.8 | -8.98 | -8.49 |